Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Other Non Operating Income (2021 - 2025)

Intellia Therapeutics (NTLA) has disclosed Other Non Operating Income for 5 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 61.27% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $28.3 million, a 85.64% increase, with the full-year FY2025 number at $28.3 million, up 85.64% from a year prior.
  • Other Non Operating Income was $2.9 million for Q4 2025 at Intellia Therapeutics, down from $10.2 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $10.2 million in Q3 2025 to a low of -$7.9 million in Q2 2024.
  • A 5-year average of $3.1 million and a median of $4.7 million in 2025 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: tumbled 2306.02% in 2022, then soared 464.03% in 2023.
  • Intellia Therapeutics' Other Non Operating Income stood at -$822000.0 in 2021, then crashed by 303.89% to -$3.3 million in 2022, then soared by 332.86% to $7.7 million in 2023, then decreased by 2.35% to $7.5 million in 2024, then tumbled by 61.27% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Other Non Operating Income are $2.9 million (Q4 2025), $10.2 million (Q3 2025), and $8.7 million (Q2 2025).